COSMOS HEALTH NEW DL-01 (V67A) - Total Liabilities
Based on the latest financial reports, COSMOS HEALTH NEW DL-01 (V67A) has total liabilities worth €47.05 Million EUR (≈ $55.01 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check V67A financial resilience to evaluate the company's liquid asset resilience ratio.
COSMOS HEALTH NEW DL-01 - Total Liabilities Trend (2021–2025)
This chart illustrates how COSMOS HEALTH NEW DL-01's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of COSMOS HEALTH NEW DL-01.
COSMOS HEALTH NEW DL-01 Competitors by Total Liabilities
The table below lists competitors of COSMOS HEALTH NEW DL-01 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
BTC Health Ltd
AU:BTC
|
Australia | AU$248.95K |
|
Pointerra Ltd
AU:3DP
|
Australia | AU$5.49 Million |
|
Minox International Group Berhad
KLSE:0288
|
Malaysia | RM23.48 Million |
|
IntegraFin Holdings plc
LSE:IHP
|
UK | GBX35.55 Billion |
|
Cocrystal Pharma Inc
NASDAQ:COCP
|
USA | $3.31 Million |
|
BIFIDO Co. Ltd
KQ:238200
|
Korea | ₩12.57 Billion |
|
INNO-GENE SA ZY -10
F:WQ3
|
Germany | €7.45 Million |
|
Applied Therapeutics Inc
NASDAQ:APLT
|
USA | $34.94 Million |
Liability Composition Analysis (2021–2025)
This chart breaks down COSMOS HEALTH NEW DL-01's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See V67A equity financing ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.00 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how COSMOS HEALTH NEW DL-01's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for COSMOS HEALTH NEW DL-01 (2021–2025)
The table below shows the annual total liabilities of COSMOS HEALTH NEW DL-01 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €47.05 Million ≈ $55.01 Million |
+58.01% |
| 2024-12-31 | €29.78 Million ≈ $34.81 Million |
-0.64% |
| 2023-12-31 | €29.97 Million ≈ $35.04 Million |
+5.60% |
| 2022-12-31 | €28.38 Million ≈ $33.18 Million |
-37.00% |
| 2021-12-31 | €45.05 Million ≈ $52.67 Million |
-- |
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, Croatia, Bulgaria, the United Arab Emirates, the United Kingdom, and Cyprus. The company offers prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It als… Read more